Candesartan Cilexetil/Nifedipine

坎地沙坦酯/硝苯地平

Report date: 2022/07/04 19:38:02

Base Information

Drug NameCandesartan Cilexetil/Nifedipine
Drug Alias NameNifedipine/Candesartan Cilexetil硝苯地平/坎地沙坦酯Candesartan Cilexetil and NifedipineNifedipine/candesartanBAY-98-7106
ClassificationSmall molecules
Mechanisms of ActionAngiotensin II Receptor Type 1 antagonistsVoltage-gated calcium channel blockers
TargetsAngiotensin II Receptor Type 1Voltage-gated calcium channel
Therapy Area/IndicationsEssential HypertensionHypertension
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[16
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaPending
Originator CompaniesBayer AG
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsEssential HypertensionHypertension

Other Information

ATC CodeN/A
Related LinksN/A